Doubts about the efficacy of tolvaptan for polycystic kidney disease.

Doubts about the efficacy of tolvaptan for polycystic kidney disease. Clin Nephrol. 2020 Jan 30;: Authors: Anderson CL PMID: 32000887 [PubMed - as supplied by publisher]
Source: Clinical Nephrology - Category: Urology & Nephrology Authors: Tags: Clin Nephrol Source Type: research

Related Links:

We describe a case of 63-year-old woman with infected cysts in the left kidney, in whom accurate diagnosis was made on FDG PET/CT. FDG PET/CT is an important investigation in patients with fever of uncertain etiology, where renal cyst infection is a possible cause, but other etiologies also need to be ruled out.
Source: Indian Journal of Radiology and Imaging - Category: Radiology Authors: Source Type: research
CONCLUSIONS: Our results indicate that blockade of LTCCs with amlodipine is effective in improving, to a certain extent, detrimental structural and functional vascular features of resistance arteries in CKD. PMID: 32215654 [PubMed - as supplied by publisher]
Source: American Journal of Hypertension - Category: Cardiology Authors: Tags: Am J Hypertens Source Type: research
Monoallelic mutations of DNAJB11 were recently described in seven pedigrees with atypical clinical presentations of autosomal dominant polycystic kidney disease. DNAJB11 encodes one of the main cofactors of the endoplasmic reticulum chaperon BiP, a heat-shock protein required for efficient protein folding and trafficking. Here we conducted an international collaborative study to better characterize the DNAJB11-associated phenotype. Thirteen different loss-of-function variants were identified in 20 new pedigrees (54 affected individuals) by targeted next-generation sequencing, whole-exome sequencing or whole-genome sequencing.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Clinical Investigation Source Type: research
Publication date: April 2020Source: American Journal of Kidney Diseases, Volume 75, Issue 4Author(s):
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Publication date: April 2020Source: American Journal of Kidney Diseases, Volume 75, Issue 4Author(s):
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Publication date: April 2020Source: American Journal of Kidney Diseases, Volume 75, Issue 4Author(s):
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
AbstractPolycystic kidney disease (PKD) leads to continuous decline of renal function by growth of renal cysts. Enhanced proliferation and transepithelial chloride secretion through cystic fibrosis transmembrane conductance regulator (CFTR) and Ca2+-activated TMEM16A Cl− channels is thought to cause an increase in cyst volume. Recent work shows the pro-proliferative role of the Ca2+ activated Cl− channel TMEM16A (anoctamin 1), and demonstrates the essential contribution of TMEM16A to CFTR-dependent Cl− secretion. The present data demonstrate an increase in intracellular Ca2+ ([Ca2+]i) signals and Cl&minus...
Source: Journal of Molecular Medicine - Category: Molecular Biology Source Type: research
This article is protected by copyright. All rights reserved. PMID: 32166738 [PubMed - as supplied by publisher]
Source: Clinical Genetics - Category: Genetics & Stem Cells Authors: Tags: Clin Genet Source Type: research
Publication date: Available online 11 March 2020Source: American Journal of Kidney DiseasesAuthor(s): Bénédicte Sautenet, Yeoungjee Cho, Talia Gutman, Gopala Rangan, Albert Ong, Arlene B. Chapman, Curie Ahn, Helen Coolican, Juliana Tze-Wah Kao, Kevin Fowler, Ron T. Gansevoort, Claire Geneste, Ronald D. Perrone, Tess Harris, Vicente E. Torres, York Pei, Jonathan C. Craig, Allison Tong, Gopala Rangan, Albert Ong
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Objective Autosomal dominant polycystic kidney disease (ADPKD) is a chronic progressive disorder with a significant disease burden leading to end-stage renal disease in more than 75% of the affected individuals. Although prediction of disease progression is highly important, all currently available biomarkers—including height-adjusted total kidney volume (htTKV)—have important drawbacks in the everyday clinical setting. Thus, the purpose of this study was to evaluate T2 mapping as a source of easily obtainable and accurate biomarkers, which are needed for improved patient counseling and selection of targeted ...
Source: Investigative Radiology - Category: Radiology Tags: Original Articles Source Type: research
More News: Polycystic Kidney Disease | Urology & Nephrology